Why analysts rate these ASX healthcare shares highly

Looking for healthcare shares to buy? Look no further…
The post Why analysts rate these ASX healthcare shares highly appeared first on The Motley Fool Australia. –

Due to ageing populations and improving technologies and treatments, demand for healthcare services is expected to grow strongly over the next few decades.

As a result, the healthcare sector could be a good place to consider investing with a long term view.

But which shares should you consider buying? Two highly rated ASX healthcare shares to consider are listed below:

Healius Ltd (ASX: HLS)

The first healthcare ASX share to look at is Healius. It is one of Australia’s largest pathology and diagnostic imaging providers offering services via a number of brands. These include Dorevitch Pathology, QML Pathology, Laverty Pathology, and Healthcare Imaging Services.

Healius was a very positive performer in FY 2021. For the 12 months ended 30 June, the company reported a 22% increase in revenue to $1,913.1 million and the doubling of its underlying EBIT to $266.5 million.

The standout performer during the year was its key Pathology business. It reported revenue growth of 25% to $1,452.1 million and EBIT growth of 103% to $252.8 million. This reflects strong demand for community and commercial COVID-19 testing.

One broker that believes there’s more to come in FY 2022 is Credit Suisse. Earlier this week the broker retained its outperform rating and lifted its price target to $5.50.

Credit Suisse is positive on the company due to its belief that COVID testing volumes will remain strong for some time to come.

Ramsay Health Care Limited (ASX: RHC)

Another ASX healthcare share to look at is Ramsay Health Care. It provides quality healthcare services to over 8 million patients each year through a network of facilities across 10 countries and over 500 locations.

Although trading conditions have been tough over the last 18 months and recent lockdowns are likely weighing on its performance, the company has been tipped to bounce back strongly. Particularly given the pent-up demand for healthcare services.

Goldman Sachs is a fan of Ramsay. It currently has a buy rating and $74.00 price target on the company’s shares.

The broker believes its valuation is undemanding for a defensive asset leveraged to improving vaccine rates and a favourable growth profile. It also notes that it has material balance sheet optionality. This could support acquisitions or share buybacks.

The post Why analysts rate these ASX healthcare shares highly appeared first on The Motley Fool Australia.

Should you invest $1,000 in Ramsay right now?

Before you consider Ramsay, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Ramsay wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Top brokers name 3 ASX shares to buy today

Here’s why the Healius (ASX:HLS) share price is storming 5% higher today
The latest ASX shares to be hit by a broker downgrade

Why Altium, BlueBet, Healius, & HUB24 shares are tumbling lower

Healius (ASX:HLS) share price sinks 10% despite 179% profit surge in FY21

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!